Until that completes and regulators review it, retatrutide remains investigational, with no marketing authorization, no licensed supply, and no approved labeling defining who it is for or how it should be used
Medications including Ozempic, Wegovy, Rybelsus, Mounjaro, and Zepbound were heavily marketed by pharmaceutical companies such as Novo Nordisk and Eli Lilly for blood sugar management, appetite reduction, and obesity treatment
I see this clinically
A case report on use of dulaglutide during the first weeks of pregnancy in woman affected by type 2 diabetes mellitus
The five qualifying conditions The five qualifying conditions for the NHS pathway under NICE TA1026 are 4 : Type 2 diabetes High blood pressure (hypertension) Cardiovascular disease (previous heart attack, stroke, angina, or coronary procedure) High cholesterol or dyslipidaemia Obstructive sleep apnoea For the private route, the Mounjaro and Wegovy product licences accept any one of these, plus prediabetes (an HbA1c blood-sugar reading between 42 and 47 mmol/mol) 1,2
.webp)
